Pharmacotherapy for social anxiety disorder (SAnD)

Williams, Taryn; Hattingh, Coenraad; Kariuki, Catherine M; Tromp, Sean; Balkom, A.J.L.M. van; Ipser, Jonathan; Stein, Dan J.

doi:10.1002/14651858.cd001206.pub3

Cited by 54 publications

(77 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should also be noted that venlafaxine, a serotonin and norepinephrine reuptake inhibitor (Williams et al . ), shows an opposite effect to fluoxetine, decreasing both S100B and related mRNA levels in the hippocampus of rats exposed to chronic unpredictable mild stress. This finding could indicate an anti‐inflammatory effect of this drug (Wang et al .…”

Section: S100b As An Active Factor In Neural Injurymentioning

confidence: 89%

“…Taken together these data suggest that the relationship between S100B and fluoxetine refer to the interactions between the S100B and serotonin systems. It should also be noted that venlafaxine, a serotonin and norepinephrine reuptake inhibitor (Williams et al 2017), shows an opposite effect to fluoxetine, decreasing both S100B and related mRNA levels in the hippocampus of rats exposed to chronic unpredictable mild stress. This finding could indicate an anti-inflammatory effect of this drug .…”

Section: Psychiatric Disordersmentioning

confidence: 99%

See 1 more Smart Citation

The S100B story: from biomarker to active factor in neural injury

Michetti

D’Ambrosi

Toesca

et al. 2018

Journal of Neurochemistry

269

238

View full text Add to dashboard Cite

S100B is a Ca -binding protein mainly concentrated in astrocytes. Its levels in biological fluids (cerebrospinal fluid, peripheral and cord blood, urine, saliva, amniotic fluid) are recognized as a reliable biomarker of active neural distress. Although the wide spectrum of diseases in which the protein is involved (acute brain injury, neurodegenerative diseases, congenital/perinatal disorders, psychiatric disorders) reduces its specificity, its levels remain an important aid in monitoring the trend of the disorder. Mounting evidence now points to S100B as a Damage-Associated Molecular Pattern molecule which, when released at high concentration, through its Receptor for Advanced Glycation Endproducts, triggers tissue reaction to damage in a series of different neural disorders. This review addresses this novel scenario, presenting data indicating that S100B levels and/or distribution in the nervous tissue of patients and/or experimental models of different neural disorders, for which the protein is used as a biomarker, are directly related to the progress of the disease: acute brain injury (ischemic/hemorrhagic stroke, traumatic injury), neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis), congenital/perinatal disorders (Down syndrome, spinocerebellar ataxia-1), psychiatric disorders (schizophrenia, mood disorders), inflammatory bowel disease. In many cases, over-expression/administration of the protein induces worsening of the disease, whereas its deletion/inactivation produces amelioration. This review points out that the pivotal role of the protein resulting from these data, opens the perspective that S100B may be regarded as a therapeutic target for these different diseases, which appear to share some common features reasonably attributable to neuroinflammation, regardless their origin.

show abstract

Section: S100b As An Active Factor In Neural Injurymentioning

confidence: 89%

Section: Psychiatric Disordersmentioning

confidence: 99%

The S100B story: from biomarker to active factor in neural injury

Michetti

D’Ambrosi

Toesca

et al. 2018

Journal of Neurochemistry

269

238

View full text Add to dashboard Cite

show abstract

“…Williams et al collect 20 studies in a meta‐analysis to investigate the effect of pharmacotherapy for social anxiety disorder. The collected studies include patients with major depressive disorder, and the effect size is the relative risk.…”

Section: Case Studiesmentioning

confidence: 99%

“…Funnel plots of the meta‐analysis by Williams et al [Colour figure can be viewed at wileyonlinelibrary.com]…”

Section: Case Studiesmentioning

confidence: 99%

Graphical augmentations to sample‐size‐based funnel plot in meta‐analysis

Lin

2019

Research Synthesis Methods

View full text Add to dashboard Cite

Assessing publication bias is a critical procedure in meta‐analyses for rating the synthesized overall evidence. Because statistical tests for publication bias are usually not powerful and only give P values that inform either the presence or absence of the bias, examining the asymmetry of funnel plots has been popular to investigate potentially missing studies and the direction of the bias. Most funnel plots present treatment effects against their standard errors, and the contours depicting studies' significance levels have been used in the plots to distinguish publication bias from other factors (such as heterogeneity and subgroup effects) that may cause the plots' asymmetry. However, treatment effects and their standard errors are frequently associated even if no publication bias exists (eg, both variables depend on the four data cells in a 2 × 2 table for the odds ratio), so standard‐error‐based funnel plots may lead to false positive conclusions when such association may not be negligible. In addition, the missingness of studies may relate to their sample sizes besides P values (which are partly determined by standard errors); studies with more samples are more likely published. Therefore, funnel plots based on sample sizes can be an alternative tool. However, the contours for standard‐error‐based funnel plots cannot be directly applied to sample‐size‐based ones. This article introduces contours for sample‐size‐based funnel plots of various effect sizes, which may help meta‐analysts properly interpret such plots' asymmetry. We provide five examples to illustrate the use of the proposed contours.

show abstract

“…In a previous epidemiological study, daily intake of SSRI was shown to reduce the risk of CRC, whereas no protective effect was found for TCAs . In addition to other drugs belonging to SSRIs (eg, fluoxetine and sertraline), paroxetine is a potent SSRI, which has proven to be effective in treating generalized anxiety and major depressive disorders . Moreover, paroxetine has been reported to have immunosuppressive effects in human lymphocytes and exerts marked cytotoxic effect in several types of cancer cells .…”

Section: Introductionmentioning

confidence: 99%

Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3

Jang

Jung

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

The concept of drug repositioning has recently received considerable attention in the field of oncology. In the present study, we propose that paroxetine can be used as a potent anticancer drug. Paroxetine, one of the selective serotonin reuptake inhibitors (SSRIs), has been widely prescribed for the treatment of depression and anxiety disorders. Recently, SSRIs have been reported to have anticancer activity in various types of cancer cells; however, the underlying mechanisms of their action are not yet known. In this study, we investigated the potential anticancer effect of paroxetine in human colorectal cancer cells, HCT116 and HT‐29. Treatment with paroxetine reduced cell viability, which was associated with marked increase in apoptosis, in both the cell lines. Also, paroxetine effectively inhibited colony formation and 3D spheroid formation. We speculated that the mode of action of paroxetine might be through the inhibition of two major receptor tyrosine kinases – MET and ERBB3 – leading to the suppression of AKT, ERK and p38 activation and induction of JNK and caspase‐3 pathways. Moreover, in vivo experiments revealed that treatment of athymic nude mice bearing HT‐29 cells with paroxetine remarkably suppressed tumour growth. In conclusion, paroxetine is a potential therapeutic option for patients with colorectal cancer.

show abstract

Pharmacotherapy for social anxiety disorder (SAnD)

Abstract: Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Analysis 5.1. Comparison Comparison 5: benzodiazepines versus placebo, Outcome 1 Clinical Global Impressions -Improvement (CGI-I) or similar scale (acute phase

Cited by 54 publications

References 189 publications

The S100B story: from biomarker to active factor in neural injury

The S100B story: from biomarker to active factor in neural injury

Graphical augmentations to sample‐size‐based funnel plot in meta‐analysis

Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3

Contact Info

Product

Resources

About